Stock market news

VEON

VEON intends to optimize its assets in those markets that do not meet the criteria in which the company wants to develop, said Kaan Terzioglu, CEO of the company. Among the criteria are: a large population, low level of 4G network penetration and financial, entertainment and educational services. Kaan Terzioglu did not specify which markets he was referring...

Beyond Meat

Beyond Meat's GAAP loss for 6 months of 2022 was $197.59 million, up 4.2 times from $46.918 million in the previous year. Revenue decreased 0.4% to $256.5 million from $257.59 million a year earlier.

Amgen

Amgen's GAAP net income for 6 months of 2022 was $2.793 billion, up 32.4% from $2.11 billion in the previous year. Revenue increased 3.3% to $12.832 billion from $12.427 billion a year earlier.

bluebird bio

Bluebird bio's GAAP loss for 6 months of 2022 was $222.29 million, down 50.3% from $447.51 million in the previous year. Revenue increased 3.3 times to $3.464 million from $1.037 million a year earlier.

Block

Block's GAAP loss for 6 months of 2022 was $416.64 million, compared to a profit of $242.69 million in the previous year. Revenue fell 14.1% to $8.365 billion from $9.738 billion a year earlier.

QuidelOrtho

QuidelOrtho's GAAP net income for 6 months of 2022 was $499.2 million, up 2.5 times from $197.2 million in the previous year. Revenue increased 2.9 times to $1.616 billion from $0.552 billion a year earlier.

X5 Retail Group

Service of express delivery of goods from Pyaterochka became available in new regions: Vologda, Syktyvkar, Yoshkar-Ola and Kaliningrad. In addition, the service covered all major cities, as well as about 90% of villages, towns and gardening communities in the Moscow region. To order delivery, you need to install the application Pyaterochka Delivery. Orders a...

ChemoCentryx

Amgen is buying ChemoCentryx for $3.7 billion, or $52 per share. The deal is scheduled to close in the fourth quarter of 2022.

Gilead Sciences

Gilead Sciences is buying MiroBio for $405 million. Via acquisition, Gilead will receive MiroBio's proprietary research platform and the entire portfolio of immuno-inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is now in Phase 1 clinical trials.

Amgen

Amgen buys ChemoCentryx for $3.7 billion, or $52 per share. ChemoCentryx developed the drug TAVNEOS to treat ANCA-associated vasculitis. Its U.S. sales in the first quarter of 2022, its first full quarter of sales, were $5.4 million. TAVNEOS is also already approved in major markets outside the U.S., including the European Union and Japan. The deal is schedu...